Gritstone bio, Inc. (GRTS)
NASDAQ: GRTS · IEX Real-Time Price · USD
0.963
+0.093 (10.66%)
At close: May 3, 2024, 4:00 PM
0.945
-0.018 (-1.84%)
After-hours: May 3, 2024, 7:58 PM EDT
Gritstone bio Revenue
In the year 2023, Gritstone bio had annual revenue of $16.34M, a decrease of -18.05%. Revenue in the quarter ending December 31, 2023 was $10.38M with 143.62% year-over-year growth.
Revenue (ttm)
$16.34M
Revenue Growth
-18.05%
P/S Ratio
6.27
Revenue / Employee
$70,753
Employees
231
Market Cap
102.43M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 16.34M | -3.60M | -18.05% |
Dec 31, 2022 | 19.95M | -28.27M | -58.63% |
Dec 31, 2021 | 48.21M | 44.18M | 1,094.30% |
Dec 31, 2020 | 4.04M | -328.00K | -7.51% |
Dec 31, 2019 | 4.37M | 3.18M | 267.73% |
Dec 31, 2018 | 1.19M | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ProPhase Labs | 44.38M |
Eton Pharmaceuticals | 32.64M |
BrainsWay | 31.79M |
Elutia | 24.75M |
Curis | 10.02M |
Cue Biopharma | 5.49M |
BioXcel Therapeutics | 1.38M |
GRTS News
- 1 day ago - Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024 - GlobeNewsWire
- 4 days ago - Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors - GlobeNewsWire
- 13 days ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS - PRNewsWire
- 18 days ago - Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE) - GlobeNewsWire
- 4 weeks ago - Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering - GlobeNewsWire
- 4 weeks ago - Gritstone bio Announces Proposed Public Offering - GlobeNewsWire
- 4 weeks ago - Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) - GlobeNewsWire
- 2 months ago - Did Gritstone bio, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate – GRTS - Accesswire